LIVER CIRRHOSIS IS NOT ASSOCIATED WITH ATROPHY OF THE SMALL INTESTINAL VILLI

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。CD最可靠的标志物是发现谷蛋白的麦醇溶蛋白组分诱导的小肠粘膜紊乱，并通过去除膳食麦醇溶蛋白得到改善。肌内抗体（EMA）和人组织转氨酶抗体（hTTG）在一般人群中对CD具有高度敏感性和特异性。肝病（LD）可产生大量非特异性抗体，LD尤其是肝硬化可改变粘膜结构。在LD中，既没有对CD血清学检测的效用进行验证，也没有报告小肠粘膜结构的发现范围。如果活检结果被用于在这些患者中建立CD的诊断，则需要验证小肠结构未被肝硬化改变。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The most reliable marker for CD is the finding of disordered small intestinal mucosa induced by the gliadin fraction of gluten and improvement by removal of dietary gliadin. Endomysial Antibody (EMA) and human Tissue Transglutaminase antibody (hTTG) are highly sensitive and specific for CD in the general population. Liver disease (LD) elicits a number of non-specific antibodies, and LD, especially cirrhosis, may alter mucosal architecture. In LD, neither validation of the utility of serologic tests for CD nor the range of findings of small bowel mucosal architecture has been reported. Verification that small bowel architecture is unaltered by cirrhosis, is required if biopsy findings are to be used to establish a diagnosis of CD in these patients.